Adlai Nortye Group Ltd.ANL
Price (close)
$15.53
Market cap
—
P/E
—
Revenue (FY)
—
Net income
-$51.9M
Dividend yield
—
1-year total return
772.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Adlai Nortye Group Ltd. does.
and developing innovative cancer therapies. Leveraging our dual R&D presence in the U.S. and China, we are building a robust pipeline
of drug candidates focused on two key areas where we believe we can make a significant difference. (1) RAS-targeting therapies: we are
tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON)
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | — | $45.7M | — | $5.0M | — |
| Net income | — | -$56.7M | -$58.8M | -$109.2M | -$51.9M |
| Free cash flow | — | -$4.1M | -$44.5M | -$56.9M | -$52.0M |
More on ANL.
- Adlai Nortye Group Ltd. summary
- Adlai Nortye Group Ltd. financial statements
- Adlai Nortye Group Ltd. key metrics
- Adlai Nortye Group Ltd. health scores and style box
- Adlai Nortye Group Ltd. earnings
- Adlai Nortye Group Ltd. dividends
- Adlai Nortye Group Ltd. valuation
- Adlai Nortye Group Ltd. ownership and insiders
- Adlai Nortye Group Ltd. peers
Figures from Adlai Nortye Group Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.